US and Israeli Leaders Aim to Reassure Rattled Investors
US and Israeli leaders are seeking to calm markets following extensive damage to Persian Gulf energy facilities. Bloomberg's Joumanna Bercetche reports from Dubai with the latest.
Amundi CIO Vincent Mortier says global markets have turned sharply more pessimistic about the length of the Iran conflict and now expect it to keep going for months. "The next coming days will be very key to define what should happen next," Mortier tells Bloomberg Television.
Darden Restaurants (NYSE:DRI) announced its financial results for the third quarter of fiscal 2026, ended February 22, 2026, reporting total sales of $3.345 billion.

Arcos Dorados Holdings (NYSE:ARCO), the world’s largest independent McDonald’s franchisee, reported record-breaking financial results for the fourth quarter and full year ended December 31, 2025.

The Cato Corporation (NYSE:CATO) announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026, showcasing a year of operational refinement and narrowed losses.

Alibaba Group Holding (NYSE:BABA) announced its financial results for the quarter ended December 31, 2025, revealing a strategic pivot toward reinvestment and market share defense.
Signet Jewelers (NYSE:SIG) today revealed its financial results for the fourth quarter and full fiscal year ended January 31, 2026, demonstrating steady operational execution in a normalizing luxury market.
Caleres (NYSE:CAL) reported financial results for the fourth quarter and full fiscal year ended January 31, 2026, highlighting a period of significant portfolio transformation and market share expansion.
Destination XL Group (NASDAQ:DXLG), the largest omni-channel specialty retailer of big and tall men’s apparel, announced its financial results for the fourth quarter and full fiscal year ended January 31, 2026.
Intuitive Machines (NASDAQ:LUNR) reported its fourth-quarter and full-year 2025 financial results on March 19, 2026, marking a pivotal shift from a specialized lunar lander developer to a diversified space infrastructure powerhouse.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.